Jayram, G., Shore, N. D., Salmasi, A., Walia, A., Aguilar, L., Burn, T., Lihou, C. F., Degaonkar, V., Goluboff, E. T., Ganapathy, D., Lerner, S. P. (2026). A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.7_suppl.tps886